Summary. Studies in vitro have shown that glycosylation of low density lipoprotein (LDL) will decrease its ability to bind to its receptor. We have evaluated the possibility that such an event might occur in vivo in diabetes by comparing the binding and degradation by normal fibroblasts and mouse peritoneal macrophages of LDL obtained from normal control subjects and patients with Type 2 (non-insulin-dependent) diabetes mellitus. When compared with control subjects, Type 2 diabetic patients had elevated fasting glucose (increased by 160%), haemoglobin Ale (increased by 75%), triglyceride (increased by 550%), and cholesterol (increased by 48%) levels. LDL from Type 2 diabetic patients displayed populations of particles with more heterogeneous hydrated densities than LDL from control subjects, with enrichment in the triglyceride content of the lighter population. 125I-LDL from normal and Type 2 diabetic subjects bound to fibroblasts with similar binding affinities and binding capacities. The kinetics of degradation of LDL from normal and Type 2 diabetic subjects by fibroblasts were also similar. Furthermore, all populations of LDL particles from Type 2 diabetic patients were bound and degraded by normal fibroblasts in identical fashions. In addition, 12SI-LDL from normal and Type 2 diabetic subjects were not bound or degraded by mouse peritoneal macrophages. It is concluded that the LDL of patients with Type 2 diabetes with moderate hyperglycaemia are not modified sufficiently to alter their normal binding and degradation by human fibroblasts or to cause their uptake by mouse peritoneal macrophages.
Low density lipoprotein (LDL) catabolism takes place via a highly regulated process of receptor-mediated endocytosis [1] . The initial step in this pathway is the recognition of the B apoprotein of LDL by specific cell surface receptors. Lysine residues of the B apoprotein have been shown to have an important role in this recognition, since chemical modification of this amino acid will lead to a loss of normal binding behaviour [2, 3] . Recent studies have demonstrated that incubation of LDL in vitro with glucose can result in glycosylation of lysine residues of LDL, with a resultant decrease in the binding of LDL to receptors on cultured human fibroblasts [4, 5] and an increase in the binding of LDL to receptors on rat peritoneal macrophages [6] . These observations raised the possibility that a similar phenomenon could occur in uncontrolled diabetes in vivo. Indeed, Schleicher et al. have recently reported that the level of glycosylated B apoprotein was increased in diabetic patients [7] . In order to evaluate whether LDL from diabetic patients displays any changes in functional behaviour, we have isolated LDL from the plasma of patients with uncontrolled Type 2 (non-insulin-dependent) diabetes, and determined the ability of this LDL to be bound and degraded by cultured normal human fibroblasts and mouse peritoneal macrophages.
Subjects and Methods

Subjects
Ten healthy normal control subjects (aged 24-55 years, mean 46 years) and seven subjects with Type 2 diabetes (aged 45~51 years, mean 56 years) were studied. None of the subjects had evidence of renal or liver disease, or a family history of hyperlipoproteinaemia. All the diabetic subjects were treated with diet alone and/or sulphonylurea therapy at the time of the study. Informed consent was obtained in all cases.
Clinical Studies
Following an overnight fast, blood was drawn for measurement of glucose [8] , insulin [9] , haemoglobin Ale (HbAI~) [10] , triglyceride [11] and cholesterol [12] concentrations. On a subsequent occasion, all 
Preparation of Lipoproteins
Blood was drawn after an overnight fast into tubes containing EDTA acid (1 mg/ml). LDL (d = 1.019-1.063) were isolated from plasma by ultracentrifugation, using solid KBr for density adjustment [13] . LDL were acetylated by the addition of acetic anhydride [2] . LDL were iodinated according to MacFarlane [14] . The lipoproteins were extensively dialyzed against 0.15 mol/1 NaC1, 0.05 mol/1 Tris-HC1 (pH 7.4) and sterilized by filtration.
Gilroy, California, USA) following the injection of 2 ml of thioglycollate medium (Bakte Bennett, Berkeley, California, USA) according to the procedure of Gallily and Feldman [16] . Each dish of adherent macrophages contained 200-250 p~g of cell protein.
Assays
Binding was assessed by incubating the cells at 37 ~ in a final volume of 1 ml containing 600 p.l of media and 5% lipoprotein deficient serum, and various concentrations of nSI-LDL (5-100 pg LDL protein). Non-specific binding was assessed by the addition of a 10-100-fold excess of radio-inert LDL to parallel dishes. After incubation (2 h for fibroblasts; 24 h for macrophages), the cells were placed on ice, the medium removed, and the dishes then washed four times with 1 ml of 0.15 mol/l NaC1, 0.05 tool/1 Tris HC1 (pH 7.4), 5 mmol/l CaCI2, and 2 mg/ml of bovine serum albumin, followed by one wash with 2 ml of the same buffer without bovine serum albumin. The cells were dissolved in 1 ml of 0.5 N NaOH, and their radioactivity determined in a gamma scintillation spectrophotometer. An aliquot of the cells was taken for determination of cellular protein content [17] . Although total binding reflects both the I:SI-LDL that is surface bound, as well as that internalized, we have expressed the results as ng LDL protein bound/mg cell protein. The degradation of ~zsI-LDL by the cells was determined by assessing the amount of radioactivity in the medium that is soluble after trichloroacetic acid (10% w/v final concentration) precipitation, and after extraction of free iodine with chloroform [15] . The results are expressed as ng LDL protein degraded/rag cell protein.
Sucrose Density Gradient
LDL from normal control subjects were iodinated with 131I; LDL from diabetic patients with 125I. Aliquots of normal a31I-LDL and diabetic a25I-LDL were then mixed and separated on a linear gradient of sucrose (8.02%-12.85%) by centrifugation at 40 000 rev/min for 18 h and fractions collected by puncturing the bottom of the tubes. Radioactivity was determined in a two-channel gamma scintillation spectrophotometer and the density of the gradient followed by refractometry.
Cell Cultures
Human skin fibroblasts were grown from explants from the foreskin of a healthy newborn and maintained in culture as described previously [15] . Experiments were performed On dishes which were approximately 75%-95% confluent and contained 400450 p~g of cell protein.
Mouse macrophages were harvested from peritoneal exudates of adult, male, Swiss-Webster mice (Simonsen Laboratories,
Results
The results in Table 1 demonstrate that the patients with Type 2 diabetes had marked fasting hyperglycaemia, associated with a 75% increase in their HbAlc levels. Postprandial excursions of plasma glucose were as high as 20-25 mmol/1, emphasizing the severity of diabetes in this problem. The insulin responses during feeding were not significantly different between diabetic and control subjects. Finally, patients with Type 2 diabetes had a sixfold higher value of fasting plasma triglyceride concentrations with a 50% elevation in their fasting serum cholesterol levels when compared with control subject (Table 1) . When LDL were isolated using conventional density adjusted ultracentrifugation methods, two popula- tions of LDL were noted in several patients with Type 2 diabetes. This was in contrast to the apparent homogeneity of LDL from normal subjects. When the isolated LDL were differentially radiolabelled and separated in a linear gradient of sucrose, the differences between the LDL from normal and diabetic subjects became clearer (Fig.l) . The normal LDL displayed a homogeneous pattern, with a mean hydrated density of 1.035. In contrast, LDL from diabetic patients were more heterogeneous, with peaks occurring at mean hydrated densities of 1.033 and 1.0375. A comparison of the lipid compositions of normal LDL and the two populations of diabetic LDL is shown in Table 2 . The diabetic LDL of greater density (peak 1) have a similar triglyceride/protein ratio and a slightly lower cholesterol/protein ratio when compared with controls; while the lighter diabetic LDL (peak 2) are enriched in triglyceride content with comparable or small increases in cholesterol/protein ratios. The binding of LDL to cultured human fibroblasts is illustrated in Figures 2 and 3 . Figure 2 displays typical curves of the binding of LDL from a normal and a diabetic subject when incubated with normal human fibroblasts in culture. LDL from normal and diabetic subjects showed high affinity, saturable binding of a similar degree. The binding results of LDL obtained from all subjects were analyzed by Scatchard plots (Fig. 3) . It is apparent that there are no differences between either the apparent binding affinities or capacities of LDL isolated from normal and diabetic subjects.
In addition, cultured fibroblasts degraded LDL obtained from normal and diabetic subjects to the same extent (Fig. 4) . The results of the degradation studies of all subjects were analyzed by Lineweaver-Burk plots, and there were no differences between either the apparent Km or Vmax for degradation of LDL obtained from normal and diabetic subjects (Fig. 5) .
In order to test the possibility that the different peaks of LDL identified in these patients might behave differently, studies were carried out comparing the two different classes of LDL seen in the plasma of patients with Type 2 diabetes. These results indicated that the Although LDL isolated from patients with Type 2 diabetes interacted normally with the LDL receptor on fibroblasts, it was possible that these LDL were modified in a manner that now would permit them to be processed by an alternate or 'scavenger' pathway, as proposed by Goldstein et al. [18, 19] . This possibility was evaluated by examining the binding and degradation of LDL by macrophages isolated from the mouse peritoneum. As reported previously [19] , chemical modification of LDL by acetylation resulted in a particle which was avidly taken up and degraded by a high affinity saturable process by mouse peritoneal macrophages (Fig.6) . In contrast, LDL isolated from patients with Type 2 diabetes failed to display any saturable binding and degradation by the mouse macrophages. In addition, LDL from normal controls behaved identically (not shown). Therefore, LDL from patients with Type 2 diabetes interacted normally with receptors on both fibroblasts and cells of the scavenger pathway.
Discussion
The results of these studies have indicated that LDL isolated from patients with Type 2 diabetes are bound and degraded normally by both human fibroblasts and mouse peritoneal macrophages. Thus, we could find no evidence that hyperglycaemia in vivo led to a change in the functional behaviour of isolated LDL. These findings are in contrast with recent reports in which glycosylation in vitro markedly altered the binding of LDL to cultured human fibroblasts [5] and rat peritoneal macrophages [6] . The fact that glycosylation in vitro altered the binding and degradation of LDL is not unexpected in light of the current knowledge. It is known that the recognition site of LDL for its receptor involves arginine and lysine residues. By blocking the amino groups of arginine with 1,2cyclohexanedione, or the e-amino groups of lysine by reductive methylation in vitro, the high affinity binding and subsequent degradation can be abolished [3, 20] . Hyperglycaemia has been shown to lead to abnormal glycosylation of haemoglobin, as well as other serum proteins, by forming a Schiff base with the e-amino groups of lysine and subsequently undergoing the non-enzymatic Amadori rearrangement to form a more stable compound [21] . Recently, LDL from diabetic patients has been reported to be similarly glycosylated [71. If the lysine residues of the apoprotein of LDL were glycosylated to a significant degree, one might expect to observe an alteration in the manner with which LDL interacts with its receptor. Therefore, it is not immediately obvious why we could not document any change in the binding or degradation of LDL isolated from patients with Type 2 diabetes. One possible explanation for the disparity of results in vitro and in vivo relates to the condition of the two kinds of studies. For example, the concentrations of glucose utilized in studies in vitro (up to 100 mmol/1) were much higher than those observed in our patients, and the incubations were maintained for a period of time greater than the normal half-life of LDL in plasma. Therefore, the fact that LDL isolated from patients with Type 2 diabetes did not express the same abnormality should not be too surprising. Although our results do not prove that glycosylation of LDL could never lead to a lipoprotein which demonstrated abnormal binding and degradation, the metabolic characteristics of our patient population suggest that this phenomenon must be limited to patients with extremely severe hyperglycaemia. The diabetes in our patients was clearly under poor control -they had significant fasting hyperglycaemia, HbA~c levels were aproximately twice-normal, and post-prandial plasma glucose concentrations were as high as 25 mmol/1. Unfortunately, our data provide no insight as to the level of hyperglycaemia that might be necessary to achieve the degree of glycosylation required to lead to abnormal LDL binding, but preliminary observations by Lopes-Virella et al. [22] lend support to the concept that subtle changes in LDL catabolism may exist in diabetes. They stated that the ability of fibroblasts to degrade LDL isolated from poorly controlled patients with Type I (insulin-dependent) diabetes was decreased, and that improved metabolic control remedied this defect. However, no changes were noted in LDL binding, and the information available does not permit a detailed comparison with our results. Nonetheless, their observations are consistent with the possibility that the LDL of at least some patients with diabetes might be altered (glycosylated) enough to lead to abnormal catabolism.
A second possible reason for the disparity between binding in vitro and in vivo relates to the catabolic rate of LDL in vivo. Thus, it is possible that a subset of LDL particles are generated in vivo which would demonstrate abnormal binding and/or degradation, but these particles may be cleared so rapidly in vivo that their isolation from plasma is impossible. Therefore, it is imperative that our results not be over-interpreted. All we can legitimately conclude is that LDL isolated from patients with a severe form of Type 2 diabetes interact normally with the LDL receptor on cultured human fibroblasts and do not interact abnormally with mouse peritoneal macrophages.
Finally, the observation that the hydrated densities of LDL from patients with Type 2 diabetes were more heterogeneous is worthy of some comment. Neither the origin nor the catabolic fate of these particles is apparent. For example, do they arise during the process of conversion of very low density lipoproteins to LDL, or subsequent to the formation of LDL? Do they only interact with the normal LDL receptor, or can they also be catabolized by alternative pathways? Answers to these questions are issues which we are currently addressing.
